- Pharmagen launches Warfarin-friendly multivitamin
- Energizer Holdings to acquire feminine hygiene business from J&J Family of Consumer Cos.
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
CHICAGO An investigational drug made by Johnson & Johnson is more effective in reducing the risk of stroke in patients with a trial fibrillation than a widely available generic, the drug maker said Monday.
J&J announced results of the phase-3 “Rocket-AF” trial of rivaroxaban, saying results showed that a once-daily dose of the drug worked better than warfarin, the most commonly used drug for preventing stroke in AF patients. Rivaroxaban also was comparable in terms of safety.
The trial involved 14,264 patients randomly selected to receive rivaroxaban or warfarin once a day. Rivaroxaban reduced the risk of stroke by 21% relative to warfarin. Patients taking rivaroxaban also had numerically fewer heart attacks, though the reduction was not significant in percentage terms, J&J said.